SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Advanced NSCLCOctober 4, 2026

Checkpoint inhibitors were associated with longer survival in NSCLC after allogeneic stem cell transplantation

Immune checkpoint inhibitors were associated with longer overall survival than chemotherapy alone in patients who developed advanced NSCLC after allogeneic HCT, in an international cohort study published in Lung Cancer. Severe immune-related toxicity and GvHD were infrequent in the lines of therapy that contained an ICI.
Share

In brief

  • An international cohort study identified 77 patients from 18 centres in six countries who were diagnosed with non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) after allogeneic hematopoietic cell transplantation (HCT).
  • In advanced NSCLC, median overall survival was 17.4 months with immune checkpoint inhibitor (ICI)-based therapy (n=20) and 4.7 months with chemotherapy alone (n=16), a hazard ratio of 0.32.
  • Grade 3–5 immune-related adverse events (irAEs) or graft-versus-host disease (GvHD) occurred in 2 of 30 ICI-containing lines of therapy (7%) and in 1 of 47 lines without an ICI (2%).
  • Patients who received ICIs began treatment a median of 7.1 years after transplantation, against 3.0 years for those who did not, and none of them required treatment for GvHD.
  • Treatment was not randomised, and the authors limit their conclusion to selected patients with presumed host immune tolerance.

Study at a glance

  • Cohort: 77 patients from 18 centres in six countries
  • Population: NSCLC or SCLC diagnosed after allogeneic HCT; median 4.2 years from transplant to diagnosis
  • Patients: 64% male; 81% current or former smokers
  • Comparison: ICI-based therapy (n=20) vs chemotherapy alone (n=16) in advanced NSCLC
  • Survival: median overall survival 17.4 vs 4.7 months; HR 0.32 (95% CI 0.13–0.77)
  • Safety: grade 3–5 irAEs or GvHD in 2 of 30 ICI-containing lines (7%) and 1 of 47 other lines (2%)
  • Not reported: in the abstract, progression-free survival, response rates and survival outcomes for the patients with SCLC

A cohort gathered across 18 centres in six countries

The investigators identified 77 people with a history of allogeneic HCT who were later diagnosed with NSCLC or SCLC, and lung cancer was diagnosed a median of 4.2 years after the transplant. Of these patients, 64% were male and 81% were current or former smokers.

The authors start from the improvement in long-term outcomes after allogeneic HCT, which makes second cancers, lung cancer among them, more relevant in transplant survivors. For these patients the clinical utility of ICIs has been unclear, and concerns about GvHD have persisted. The study evaluated clinical characteristics, survival and toxicity in this group.

A median overall survival of 17.4 months with checkpoint inhibitors against 4.7 months with chemotherapy

Among patients with advanced NSCLC, the 20 who received ICI-based therapy had a hazard ratio for death of 0.32 (95% CI 0.13–0.77) when compared with the 16 who were treated with chemotherapy alone.

The comparison rests on 36 patients, and treatment in this cohort was not assigned at random. The confidence interval is wide, running from a 23% to an 87% reduction in the hazard of death. The abstract reports the association; it does not describe an adjustment for the differences between the two groups.

Severe immune toxicity or GvHD in 2 of 30 checkpoint inhibitor lines

Across 77 lines of systemic therapy given to 54 patients, grade 3–5 irAEs or GvHD occurred in 7% of the ICI-containing lines and in 2% of the lines without an ICI.

The authors report that they did not observe a clear signal of excess irAEs or GvHD. The counts are small, with three events in total across both groups, so the study can describe the toxicity seen but cannot estimate the difference between the groups with any precision.

Patients given checkpoint inhibitors were further from their transplant

The median interval from HCT to the start of treatment was 7.1 years in patients who received an ICI and 3.0 years in those who did not. No patient in the ICI group required treatment for GvHD, compared with 25% of the patients who were treated without an ICI.

The authors interpret these differences as an indication of improved host immune tolerance in the patients who were given ICIs. The patients selected for checkpoint blockade therefore differed from the comparison group before treatment began, and the survival comparison carries that difference with it.

“In our study, ICI-based therapies were associated with prolonged survival in selected patients with advanced NSCLC and presumed host immune tolerance.”Rost et al., Lung Cancer (2026)

The authors support considering ICIs in transplant survivors with lung cancer

On the basis of these results, the authors conclude that their results support considering the use of ICIs in this population. Their conclusion is restricted to selected patients, and the comparison behind it is observational and small, with fewer than 40 patients with advanced NSCLC in the survival analysis.

Sources

  1. Lung Cancer. Lung cancer after allogeneic hematopoietic stem cell transplantation (2026-09-01). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Nikolaj Frost, Martin Reck and Alessio Cortellini.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Nov 13 2026
ILCS 2026
Advanced NSCLCResectable NSCLCSCLC

Panel: open questions & patient cases

Nov 13 2026
ILCS 2026
SCLC

Debate: which is the better choice in 1L ES-SCLC?

G. MountziosA. Dingemans
Nov 13 2026
ILCS 2026
SCLC

The emerging role of T-cell engagers and ADCs in SCLC

N. Frost
Nov 13 2026
ILCS 2026
Advanced NSCLC

New compounds and combinations for non-oncogene-addicted advanced NSCLC

A. Cortellini
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCResectable NSCLCTargeted Therapies

One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey

M. Hochmair
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C

A. Curioni-Fontecedro
Nov 13 2026
ILCS 2026
Advanced NSCLCADCs

The ADC wave: integrating new agents in NSCLC

D. Planchard
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Targeting (K)RAS with new compounds

C. Lovly
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Other actionable genomic alterations, incl. HER2 and ROS1

T. Sequeira
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

New standards in EGFR- and ALK-positive NSCLC

H. Horinouchi
Dr. Jacob Sands
Nov 04 2026
SPONSORED INTERVIEW
SCLCImmunotherapies

New Therapy Options in SCLC and AE Management

Dr. Jacob Sands discusses new treatment options in small cell lung cancer and the management of their adverse events in this on-demand expert interview.

J. Sands
Oct252026
ESMO 2026 SYMPOSIUM
SCLCImmunotherapies

SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era

A symposium at ESMO Congress 2026 on small-cell lung cancer, from immunotherapy standards to the emerging era of DLL3 T-cell engagers. Recording to follow.

M. ReckS. PetersG. MountziosN. Reguart
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
SCLC

Reshaping Approaches in SCLC with the Latest Advances in LS- and ES-Disease

} 34 min

R. Manochakian
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Sep 26 2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro
Articles
Nov 16 2026
RESEARCH
Advanced NSCLCResectable NSCLC

South Asian experts agree consensus recommendations for NSCLC, with low-cost options built in

V. Noronha
Nikolaj Frost
Nov 15 2026
RESEARCH
Advanced NSCLCResectable NSCLC

A 454-patient single-cell atlas links NSCLC tumour cell states to metastasis and survival

N. Frost
Charles Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide

C. Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCBiomarkersADCs

Membrane share of TROP2 identified longer PFS on Dato-DXd in nonsquamous NSCLC

J. SandsM. PérolN. Girard
Nov 12 2026
RESEARCH
BiomarkersResectable NSCLCTargeted Therapies

MTAP loss seen in 17% of NSCLC by immunohistochemistry, with PRMT5 inhibitors active in TKI-resistant cells

Z. Piotrowska
Nov 04 2026
RESEARCH
Advanced NSCLCImmunotherapies

Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC

A. FilippiL. Hendriks
Nov 01 2026
RESEARCH
Advanced NSCLCBiomarkersTargeted Therapies

Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling

P. Hofman
Oct 31 2026
RESEARCH
Advanced NSCLCTargeted Therapies

VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries

A. Cortellini
Charles Rudin
Oct 30 2026
RESEARCH
SCLCImmunotherapies

Tarlatamab gave an mOS of 13.6 months against 8.4 with chemotherapy in SCLC at extended DeLLphi-304 follow-up

C. RudinG. Mountzios
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
Advanced NSCLCImmunotherapies

Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE

M. Pérol
Oct 27 2026
RESEARCH
SCLCImmunotherapies

Tarlatamab added to durvalumab maintenance extended OS in extensive-stage SCLC

J. SandsM. PérolA. Dingemans
Oct 26 2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies

Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC

Oct 23 2026
RESEARCH
SCLCImmunotherapies

KEYVIBE-008 tested vibostolimab coformulated with pembrolizumab plus chemotherapy in first-line ES-SCLC

J. SandsM. Reck
Oct 22 2026
RESEARCH
Advanced NSCLC

TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients

R. StahelL. BubendorfL. HendriksS. PetersS. Finn
Oct 21 2026
SPONSORED
Advanced NSCLCImmunotherapies

The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC

A. Curioni-Fontecedro
Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 19 2026
RESEARCH
Advanced NSCLCImmunotherapies

Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update

H. Horinouchi
Oct 18 2026
RESEARCH
Advanced NSCLCTargeted Therapies

First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg

X. LeD. PlanchardM. Pérol
Oct 16 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months

A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti